Loky do ★ Egypt, 2021-03-29 17:59 (1501 d 20:38 ago) Posting: # 22297 Views: 3,632 |
|
Dears If subject during bioequivalence study suffered from diarrhea before 2 median Tmax of immediate-release drug product, in this case, the optimum action to be done to exclude the subject from the study after the event directly? or subject continues the study and excludes his results from the calculations if his plasma concentration-time profile is unreliable? Thanks in advance Edit: Category changed; see also this post #1. [Helmut] |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2021-03-29 20:08 (1501 d 18:29 ago) @ Loky do Posting: # 22298 Views: 2,851 |
|
Hi Loky do, ❝ If subject during bioequivalence study suffered from diarrhea before 2 median Tmax of immediate-release drug product, in this case, the optimum action to be done to exclude the subject from the study after the event directly? If you know the median tmax. ![]() State in the statistical analysis plan, and follow it (analyse the samples anyway). ❝ or subject continues the study and excludes his results from the calculations if his plasma concentration-time profile is unreliable? I would not recommend that. Who / how decides what is ‘unreliable’? May lead to endless & fruitless discussions. — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
dshah ★★ India, 2021-03-31 16:43 (1499 d 21:54 ago) @ Loky do Posting: # 22299 Views: 2,849 |
|
Dear Loky do, It is always beneficial to mention exclusion parameters in Protocol. Generally diarrhea is going to impact gastric motility and thus absorption of drug. PI shall exclude such subjects. Regards, Dshah |